Galectin Therapeutics (GALT) Liabilities and Shareholders Equity (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Liabilities and Shareholders Equity of $15.8 million for Q1 2026, up 65.4% year-over-year from $9.5 million in Q1 2025, and down 19.32% quarter-over-quarter from $19.5 million in Q4 2025.
Galectin Therapeutics (GALT) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 65.4% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $63.8 million (down 23.78% YoY), while the FY2025 annual figure was $19.5 million, up 11.64% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $15.8 million, down from $19.5 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $33.6 million in Q1 2022, with the low at $9.5 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $20.2 million (2023), against an average of $21.3 million.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 63.2% in 2025, then soared 65.4% in 2026.
- Galectin Therapeutics' Liabilities and Shareholders Equity stood at $21.3 million in 2022, then soared by 32.49% to $28.2 million in 2023, then slumped by 37.96% to $17.5 million in 2024, then increased by 11.64% to $19.5 million in 2025, then dropped by 19.32% to $15.8 million in 2026.
- Business Quant data shows GALT's Liabilities and Shareholders Equity at $15.8 million in Q1 2026, $19.5 million in Q4 2025, and $12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.76 Mn |
| Dec 31, 2025 | 19.53 Mn |
| Sep 30, 2025 | 12.87 Mn |
| Jun 30, 2025 | 15.60 Mn |
| Mar 31, 2025 | 9.53 Mn |
| Dec 31, 2024 | 17.50 Mn |
| Sep 30, 2024 | 28.97 Mn |
| Jun 30, 2024 | 27.66 Mn |
| Mar 31, 2024 | 25.89 Mn |
| Dec 31, 2023 | 28.20 Mn |
| Sep 30, 2023 | 22.16 Mn |
| Jun 30, 2023 | 20.08 Mn |
| Mar 31, 2023 | 20.23 Mn |
| Dec 31, 2022 | 21.29 Mn |
| Sep 30, 2022 | 17.91 Mn |
| Jun 30, 2022 | 25.89 Mn |
| Mar 31, 2022 | 33.62 Mn |
| Dec 31, 2021 | 41.83 Mn |
| Sep 30, 2021 | 38.04 Mn |
| Jun 30, 2021 | 33.41 Mn |